The Supreme Court on Oct. 1 turned down an appeal by Pfizer Inc. aimed at preventing the sale of a generic version of its best-selling drug for high blood pressure. The New York-based pharmaceutical giant had asked the court to overturn an appeals court ruling earlier this year, which determined that Pfizer's Norvasc patent is invalid. The justices declined to hear Pfizer's appeal.
October 02, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
The Supreme Court on Oct. 1 turned down an appeal by Pfizer Inc. aimed at preventing the sale of a generic version of its best-selling drug for high blood pressure.
The New York-based pharmaceutical giant had asked the court to overturn an appeals court ruling earlier this year, which determined that Pfizer’s Norvasc patent is invalid. The justices declined to hear Pfizer’s appeal.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
